Unknown

Dataset Information

Brolucizumab in recalcitrant neovascular age-related macular degeneration-real-world data in Chinese population.


ABSTRACT: This retrospective study aimed to determine the short-term efficacy and safety of brolucizumab treatment for recalcitrant neovascular age-related macular degeneration (nAMD) in a real-world setting in Taiwan. Recalcitrant nAMD patients who were treated with brolucizumab from November 2021 to August 2022 at Taipei Veterans General Hospital were included. Patients were followed for 3 months after switching to brolucizumab. The primary outcomes were changes in mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) from baseline to the third month. The secondary outcomes included the incidence of intraocular inflammation (IOI), proportion of patients with subretinal and intraretinal fluid (SRF and IRF), and change in pigment epithelial detachment (PED) height from baselin

SUBMITTER: Weng CC 

PROVIDER: S-EPMC10986944 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature